Skip to main content

Table 1 Summary of clinicopathological data

From: Predominance of CIN versus MSI in the development of rectal cancer at young age

Tumor no. Sex/age Family history (No, Am, Fa, Ud) Tumor location Pre-op radio-therapy Dukes'/TNM stage Diff. grade Adjuvant chemo-therapy Met.free/overall survival (mo.)
1 25/F No m + C/T4N1M0 mo FLV 46
2 31/F No h + C/T3N1M0 mo FLV 84
3 32/M Fa m + D/T4N1M1 mo FLV+OX 0/15
4 32/M No m + B/T3N0M0 mo FLV 33
5 33/M No m + B/T3N0M0 mo - 85
6 37/M No h - B/T3N0M0 mo - 80
7 38/M No m + A/T2N0M0 mo - 61
8 38/M Am h - A/T1N0M0 we - 49
9 39/M Ud l + D/T4N2M1 mu, si - 0/8
10 39/F Am h - A/T2N0M0 mo - 32
11 41/M No h + A/T2N0M0 mu - 35
12 41/M Fa h + B/T3N0M0 mo FLV 34
13 42/M Fa l + C/T3N1M0 mo FLV 27
14 43/F No h + D/T4N2M1 mo FLV 0/20
15 43/M No m + C/T3N1M0 mo FLV 46
16 44/M No m + B/T3N0M0 po - 19
17 44/F Fa m - C/T3N1M0 mu FLV 10/22
18 45/M No m + B/T3N0M0 mo - 71
19 45/M No h + C/T4N1M0 mo FLV 55
20 47/M No m - C/T3N1M0 mo - 28
21 47/F Fa l + C/T3N1M0 mo FLV 24
22 47/M No m - D/T3N0M1 mo FLV 0/40
23 47/F No l + C/T3N2M0 mu, si FLV 11/17
24 48/M No h + D/T4N2M1 mo FLV 0/24
25 49/M No h + D/T4N2M1 mu FLV 0/3
26 49/M Ud h + C/T3N1M0 mo FLV 27/38
27 49/M No h - C/T3N2M0 mo - 62
28 49/M No m + A/T2N0M0 mo - 37
29 49/F No m + A/T2N0M0 mo - 72
30 49/F Fa l + C/T3N1M0 mo - 71
  1. Abbreviations: family history; Am: Amsterdam II criteria fulfilled, Fa: familial, No: no history; Ud:undetermined tumor location; h:high, m:middle, l:low differentiation; we:well, mo:moderate, po:poor, mu:mucinous, si:signet ring cell FLV; 5-FU + leucovorin